The vaccine will be manufactured by Hyderabad-based Shantha Biotechnics Private Limited, an affiliate of Sanofi Pasteur.
Shantha will provide 2.3 million doses of ShanIPV in 2015, and 9 million in 2016 to Unicef for India's needs. The company plans to produce a total of over 10 million doses in 2016 with additional increases planned in subsequent years, the company said.
Injectable IPV is a part of WHO led initiative to move from oral administration of polio vaccine to injectables.
"Today, we are proud to further strengthen our commitment towards disease prevention and support the Indian Government's universal immunisation programme, including polio eradication. With the introduction of IPV in the immunisation schedule, our company is playing a key role in achieving the goal of a polio-free world,"said Shailesh Ayyangar, managing director- India and vice president-South Asia,of Sanofi.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)